These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 18332284)

  • 1. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
    van den Born BJ; van der Hoeven NV; Groot E; Lenting PJ; Meijers JC; Levi M; van Montfrans GA
    Hypertension; 2008 Apr; 51(4):862-6. PubMed ID: 18332284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
    Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
    Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential therapeutic benefit of targeting ADAMTS13 activity.
    Eerenberg ES; Levi M
    Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.
    Claus RA; Bockmeyer CL; Budde U; Kentouche K; Sossdorf M; Hilberg T; Schneppenheim R; Reinhart K; Bauer M; Brunkhorst FM; Lösche W
    Thromb Haemost; 2009 Feb; 101(2):239-47. PubMed ID: 19190805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
    Shibagaki Y; Fujita T
    Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
    Kobayashi T; Wada H; Nishioka N; Yamamoto M; Matsumoto T; Tamaru T; Nomura S; Masuya M; Mori Y; Nakatani K; Nishikawa M; Katayama N; Nobori T
    Thromb Res; 2008; 121(6):849-54. PubMed ID: 17900666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13.
    Löwenberg EC; Charunwatthana P; Cohen S; van den Born BJ; Meijers JC; Yunus EB; Hassan MU; Hoque G; Maude RJ; Nuchsongsin F; Levi M; Dondorp AM
    Thromb Haemost; 2010 Jan; 103(1):181-7. PubMed ID: 20062916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
    Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P
    Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
    Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
    Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
    Schiphorst RH; van de Kar NC; van den Heuvel LP
    Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
    Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
    Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM; Lian EC
    N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2015; 2015(1):631-6. PubMed ID: 26637781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
    Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
    Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
    Feys HB; Canciani MT; Peyvandi F; Deckmyn H; Vanhoorelbeke K; Mannucci PM
    Br J Haematol; 2007 Aug; 138(4):534-40. PubMed ID: 17608762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased von Willebrand Factor to ADAMTS13 ratio as a predictor of thrombotic complications following a major hepatectomy.
    Kobayashi S; Yokoyama Y; Matsushita T; Kainuma M; Ebata T; Igami T; Sugawara G; Takahashi Y; Nagino M
    Arch Surg; 2012 Oct; 147(10):909-17. PubMed ID: 23117828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation.
    Kentouche K; Zintl F; Angerhaus D; Fuchs D; Hermann J; Schneppenheim R; Budde U
    Semin Thromb Hemost; 2006 Mar; 32(2):98-104. PubMed ID: 16575684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.
    Franchini M; Montagnana M; Targher G; Lippi G
    Semin Thromb Hemost; 2007 Nov; 33(8):787-97. PubMed ID: 18175284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.